If you’ve been following the weight loss medication space, you’ve likely heard about a new dual-agonist peptide making waves in clinical trials. Based on our research into the latest studies, mazdutide represents a significant advancement in metabolic therapy.
Mazdutide is a once-weekly injectable peptide that activates both GLP-1 and glucagon receptors, and it’s showing impressive results in clinical trials with up to 20.1% weight loss.
I’ve spent considerable time reviewing the published research on this peptide, including Phase 3 trial data from NEJM and Nature. The head-to-head comparison against semaglutide caught my attention, showing mazdutide’s clear superiority in certain outcomes.
In this comprehensive guide, I’ll break down everything we know about mazdutide in 2026, from its unique dual mechanism to the latest clinical trial results and what it might mean for the future of weight management.
ContentsTable of Contents
- 1What Is Mazdutide?→
- 2Who Developed Mazdutide?→
- 3Current Approval Status→
- 4How Mazdutide Works?→
- 5The GLP-1 Pathway→
- 6The Glucagon Pathway→
- 7The Synergy Effect→
- 8Clinical Trial Results→
- 9The GLORY Weight Loss Trials→
- 10The DREAMS Diabetes Trials→
- 11Head-to-Head Trial vs Semaglutide→
- 12Mazdutide Weight Loss Results→
- 13Weight Loss by Dose→
- 14How This Compares to Other Treatments→
- 15Mazdutide for Type 2 Diabetes→
- 16Blood Sugar Control Results→
- 17Why Dual Action May Matter for Diabetes?→
- 18Other Potential Benefits→
- 19Liver Health (NAFLD/NASH)→
- 20Cardiovascular Markers→
- 21Emerging Research Areas→
- 22Side Effects and Safety Profile→
- 23Common Side Effects→
- 24Tolerability Considerations→
- 25Who Should Avoid Mazdutide→
- 26Dosing and Administration→
- 27Titration Schedule→
- 28Administration Tips→
- 29Mazdutide vs Other GLP-1 Medications→
- 30Mechanism Comparison→
- 31Key Differences→
- 32Frequently Asked Questions→
- 33What does mazdutide peptide do?→
- 34What is the average weight loss on mazdutide?→
- 35What are the side effects of mazdutide?→
- 36Is mazdutide a once-daily injection?→
- 37How effective is mazdutide compared to semaglutide?→
- 38Is mazdutide approved by the FDA?→
- 39What is the difference between mazdutide and tirzepatide?→
- 40The Bottom Line→
What Is Mazdutide?
Mazdutide is a once-weekly injectable peptide that acts as a dual agonist of GLP-1 (glucagon-like peptide-1) and glucagon receptors, developed for treating obesity and type 2 diabetes.
This peptide goes by several names in scientific literature and regulatory filings. You may see it referred to as IBI362 (the clinical trial designation), LY3305677 (Eli Lilly’s development code), or Xinermei (the brand name approved in China).
Mazdutide: A synthetic oxyntomodulin analog that simultaneously activates GLP-1 receptors (for appetite control) and glucagon receptors (for increased energy expenditure), creating a dual approach to weight management.
Who Developed Mazdutide?
Mazdutide was originally developed by Eli Lilly in the United States. The company later licensed the rights to Innovent Biologics, a Chinese biotechnology company, for development in China.
Innovent Biologics has led the clinical development program, completing multiple Phase 3 trials. In June 2025, China’s National Medical Products Administration (NMPA) approved mazdutide for chronic weight management, making it the world’s first approved dual GCG/GLP-1 receptor agonist for this indication.
Current Approval Status
As of 2026, mazdutide’s regulatory status varies by region:
- China: Approved by NMPA in June 2025 for chronic weight management and type 2 diabetes
- United States: Currently in Phase 2 trials; FDA approval expected 2026-2027
- Europe: Clinical trials ongoing; EMA submission timeline pending
- United Kingdom: Not yet approved; awaiting trial completion
How Mazdutide Works?
Mazdutide works by activating two key receptor pathways simultaneously: GLP-1 receptors and glucagon receptors. This dual mechanism creates complementary effects that may enhance overall metabolic benefits.
Understanding how this peptide functions requires looking at each pathway individually, then seeing how they work together.
The GLP-1 Pathway
When mazdutide binds to GLP-1 receptors, several metabolic effects occur:
- Appetite Suppression: Signals to the brain reduce hunger and increase feelings of fullness
- Slowed Gastric Emptying: Food stays in the stomach longer, prolonging satiety
- Enhanced Insulin Secretion: The pancreas releases more insulin in response to food (glucose-dependent)
- Reduced Glucagon Release: Less glucagon means lower blood sugar levels after meals
This pathway is the same mechanism used by semaglutide (Wegovy/Ozempic) and other GLP-1 medications already on the market.
The Glucagon Pathway
What makes mazdutide unique is its additional activation of glucagon receptors. This pathway provides benefits that GLP-1 alone cannot offer:
- Increased Energy Expenditure: The body burns more calories at rest through thermogenesis
- Enhanced Fat Oxidation: The liver metabolizes stored fat more efficiently
- Improved Lipid Metabolism: May help reduce liver fat and improve cholesterol profiles
The Synergy Effect
The combination of these two pathways creates a synergistic effect. While GLP-1 activation reduces calorie intake through appetite suppression, glucagon activation increases calorie output through enhanced metabolism.
Clinical researchers describe this as addressing both sides of the energy balance equation. Based on trial data, this dual approach may explain why mazdutide shows superior weight loss compared to GLP-1-only medications in some studies.
Key Distinction: While tirzepatide (Mounjaro) is also a dual agonist, it targets GLP-1 and GIP receptors. Mazdutide targets GLP-1 and glucagon receptors, which are entirely different mechanisms.
Clinical Trial Results
Mazdutide has been evaluated in extensive clinical trial programs, with results published in major medical journals including the New England Journal of Medicine and Nature. The evidence base includes both the GLORY program (for weight management) and the DREAMS program (for type 2 diabetes).
The GLORY Weight Loss Trials
The GLORY clinical trial program evaluated mazdutide specifically for weight management in adults with obesity or overweight.
GLORY-1 Trial Results:
This Phase 3 trial enrolled adults with obesity or overweight. At 48 weeks, participants achieved significant weight loss:
- 4mg dose: Approximately 11% average body weight reduction
- 6mg dose: Approximately 14% average body weight reduction
- Placebo: Minimal weight change
GLORY-2 Trial Results:
The follow-up GLORY-2 trial tested higher doses over a longer period. Results announced in November 2025 showed:
- 9mg dose at 60 weeks: Up to 20.1% average body weight reduction
- Higher doses demonstrated dose-dependent efficacy increases
The DREAMS Diabetes Trials
The DREAMS program evaluated mazdutide in patients with type 2 diabetes, focusing on both glycemic control and weight outcomes.
Key DREAMS Trial Findings:
- Significant HbA1c reductions across all doses tested
- Dual benefit of blood sugar control plus weight loss
- Favorable safety profile consistent with GLP-1 class
Head-to-Head Trial vs Semaglutide
One of the most significant findings came from the DREAMS-3 trial, which directly compared mazdutide to semaglutide. Published in October 2025, this head-to-head comparison showed mazdutide’s superiority:
| Outcome | Mazdutide | Semaglutide |
|---|---|---|
| Patients achieving HbA1c under 7% AND 10%+ weight loss | 48% | 21% |
| Combined endpoint achievement | Superior | Standard |
This head-to-head data is particularly significant because semaglutide is currently considered the gold standard in GLP-1 therapy. Mazdutide’s superiority in achieving combined weight and glycemic endpoints suggests the dual mechanism provides meaningful clinical advantages.
Mazdutide Weight Loss Results
In clinical trials, mazdutide users achieved average weight loss ranging from 11% to 20.1% depending on dose and treatment duration, placing it among the most effective weight loss medications studied to date.
The weight loss results show a clear dose-response relationship. Higher doses of mazdutide produce greater weight reduction, though they also come with consideration of tolerability.
Weight Loss by Dose
| Dose | Duration | Average Weight Loss | Trial |
|---|---|---|---|
| 3mg | 48 weeks | ~8-10% | Phase 2 |
| 4mg | 48 weeks | ~11% | GLORY-1 |
| 6mg | 48 weeks | ~14% | GLORY-1 |
| 9mg | 60 weeks | ~18-20% | GLORY-2 |
How This Compares to Other Treatments
To put mazdutide’s results in context:
- Semaglutide (Wegovy): Approximately 15% weight loss at 68 weeks in the STEP trials
- Tirzepatide (Zepbound): Up to 22.5% weight loss at highest doses in the SURMOUNT trials
- Mazdutide: Up to 20.1% weight loss in GLORY-2, with superiority vs semaglutide in head-to-head
Based on available data, mazdutide appears to fall between semaglutide and tirzepatide in terms of maximum weight loss, while showing superiority to semaglutide when both weight loss and glycemic control are measured together.
Pro Tip: When comparing weight loss medications, consider that trial populations and durations differ. Head-to-head trials like DREAMS-3 provide the most reliable comparisons.
Mazdutide for Type 2 Diabetes
Mazdutide has shown significant benefits for type 2 diabetes management, with clinical trial data demonstrating meaningful reductions in HbA1c alongside weight loss benefits.
For patients with type 2 diabetes, the dual benefit of blood sugar control and weight management is particularly valuable, as excess weight often contributes to insulin resistance.
Blood Sugar Control Results
In the DREAMS clinical trial program, mazdutide demonstrated:
- HbA1c Reduction: Significant decreases across all doses tested, with higher doses showing greater reductions
- Combined Endpoints: 48% of patients achieved both HbA1c under 7% AND 10%+ weight loss (vs 21% with semaglutide)
- Insulin Sensitivity: Improvements in how the body responds to insulin
Why Dual Action May Matter for Diabetes?
The glucagon receptor activation in mazdutide may provide additional benefits beyond what GLP-1-only medications offer. Glucagon receptor stimulation can help:
- Reduce liver fat accumulation (common in type 2 diabetes)
- Improve overall metabolic function
- Enhance weight loss, which itself improves insulin sensitivity
China’s NMPA approved mazdutide for type 2 diabetes in addition to weight management, recognizing these dual benefits.
Other Potential Benefits
Beyond weight loss and diabetes management, emerging research suggests mazdutide may offer additional metabolic benefits. While more research is needed, early data points to several promising areas.
Liver Health (NAFLD/NASH)
Clinical studies suggest mazdutide may help reduce liver fat accumulation. In trials, participants showed improvements in:
- Liver fat content reduction
- Markers of liver inflammation
- Overall metabolic liver health
The glucagon pathway specifically appears to enhance hepatic fat oxidation, which may explain these liver-related benefits.
Cardiovascular Markers
Early data indicates potential cardiovascular benefits, including improvements in:
- Lipid profiles (cholesterol and triglycerides)
- Blood pressure reduction
- Inflammatory markers
However, dedicated cardiovascular outcomes trials have not yet been completed for mazdutide.
Emerging Research Areas
Based on recent publications, researchers are exploring mazdutide’s potential in:
- Cognitive Function: A Lancet study suggested possible benefits for cognitive deficits associated with metabolic disorders
- Sleep Apnea: Like other GLP-1 medications, weight loss may improve obstructive sleep apnea
- Adolescent Obesity: December 2025 data showed promising results in younger populations
Research Note: Many of these benefits are based on early or observational data. More research is needed to confirm these potential applications.
Side Effects and Safety Profile
The most common mazdutide side effects are gastrointestinal, including nausea, vomiting, diarrhea, and decreased appetite. These side effects are consistent with other GLP-1 medications and typically decrease over time.
Based on clinical trial data, mazdutide appears to have a safety profile similar to other medications in the GLP-1 class.
Common Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Nausea | Common | Mild to moderate |
| Vomiting | Common | Mild to moderate |
| Diarrhea | Common | Mild to moderate |
| Decreased appetite | Common | Expected effect |
| Abdominal distension | Less common | Mild |
| Upper respiratory infection | Less common | Mild |
Tolerability Considerations
Most gastrointestinal side effects occur during the initial dose titration period and tend to decrease as the body adjusts to the medication. The slow dose escalation schedule is designed to minimize these effects.
In clinical trials, the majority of side effects were classified as mild to moderate. Serious adverse events were rare and similar in frequency to placebo groups.
Who Should Avoid Mazdutide
Based on GLP-1 class safety data, mazdutide may not be appropriate for:
- Individuals with personal or family history of medullary thyroid carcinoma
- Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Those with severe gastrointestinal conditions
- Pregnant or breastfeeding women
Dosing and Administration
Mazdutide is administered as a once-weekly subcutaneous injection using a prefilled autoinjector. The medication is injected under the skin, typically in the stomach area, thigh, or upper arm.
Titration Schedule
Like other GLP-1 medications, mazdutide follows a gradual dose escalation schedule to improve tolerability:
| Week | Dose | Purpose |
|---|---|---|
| Weeks 1-4 | Starting dose (1-2mg) | Initial tolerability |
| Weeks 5-8 | Intermediate dose (3mg) | Gradual adjustment |
| Weeks 9-12 | Higher dose (4-6mg) | Therapeutic effect |
| Week 13+ | Maintenance dose (up to 9mg) | Optimal efficacy |
The exact titration schedule may vary based on individual tolerability and clinical response.
Administration Tips
- Inject on the same day each week
- Rotate injection sites to prevent lipodystrophy
- Store according to manufacturer guidelines
- Follow healthcare provider instructions for dose adjustments
Mazdutide vs Other GLP-1 Medications
Mazdutide is one of several next-generation peptide therapies being developed for weight management and diabetes. Understanding how it compares to other options can help contextualize its potential place in treatment.
Mechanism Comparison
| Medication | Mechanism | Targets | Status |
|---|---|---|---|
| Semaglutide (Wegovy) | Single agonist | GLP-1 | FDA approved |
| Tirzepatide (Zepbound) | Dual agonist | GLP-1 + GIP | FDA approved |
| Mazdutide | Dual agonist | GLP-1 + Glucagon | Approved in China |
| Survodutide | Dual agonist | GLP-1 + Glucagon | Phase 3 trials |
| Retatrutide | Triple agonist | GLP-1 + GIP + Glucagon | Phase 3 trials |
Key Differences
Mazdutide vs Semaglutide: Mazdutide adds glucagon activation for increased energy expenditure. Head-to-head trials showed mazdutide superiority for combined weight loss and glycemic endpoints.
Mazdutide vs Tirzepatide: Different dual mechanisms. Tirzepatide targets GIP (which enhances insulin) while mazdutide targets glucagon (which increases metabolism). Both show strong efficacy.
Mazdutide vs Retatrutide: Retatrutide is a triple agonist that includes all three receptors. Early data suggests retatrutide may have higher maximum weight loss (24%+), but it remains in clinical trials.
Frequently Asked Questions
What does mazdutide peptide do?
Mazdutide is a dual GLP-1 and glucagon receptor agonist that helps regulate appetite, metabolism, and blood sugar. It suppresses hunger through GLP-1 activation while simultaneously boosting energy expenditure and fat burning through glucagon receptor activation, making it effective for both weight loss and type 2 diabetes management.
What is the average weight loss on mazdutide?
In clinical trials, mazdutide users achieved average weight loss of 11-14% at 48 weeks on standard doses (4mg-6mg). Higher doses (9mg) showed up to 18-20% weight loss at 60 weeks, with some participants in GLORY-2 achieving 20.1% body weight reduction.
What are the side effects of mazdutide?
Common mazdutide side effects are primarily gastrointestinal and include nausea, vomiting, diarrhea, decreased appetite, abdominal distension (bloating), and upper respiratory tract infections. Most side effects are mild to moderate and tend to decrease over time as the body adjusts to the medication.
Is mazdutide a once-daily injection?
No, mazdutide is a once-weekly injection, not daily. It is administered subcutaneously (under the skin) using a prefilled autoinjector, typically in the stomach area, thigh, or upper arm. This weekly dosing makes it more convenient than daily medication options.
How effective is mazdutide compared to semaglutide?
In the DREAMS-3 head-to-head trial, mazdutide showed superiority to semaglutide for combined endpoints. 48% of patients on mazdutide achieved both HbA1c under 7% AND 10%+ weight loss, compared to only 21% on semaglutide. This suggests mazdutide’s dual mechanism provides meaningful clinical advantages.
Is mazdutide approved by the FDA?
As of 2026, mazdutide is not FDA-approved in the United States. It received approval from China’s NMPA in June 2025 for chronic weight management and type 2 diabetes. US FDA approval is expected in 2026-2027 pending successful completion of ongoing clinical trials.
What is the difference between mazdutide and tirzepatide?
Both are dual agonists, but they target different receptor combinations. Mazdutide targets GLP-1 and glucagon receptors (increasing energy expenditure), while tirzepatide targets GLP-1 and GIP receptors (enhancing insulin sensitivity). Both show strong weight loss efficacy through different mechanisms.
The Bottom Line
Mazdutide represents a significant advancement in metabolic therapy, offering a unique dual-agonist approach that targets both appetite reduction and increased energy expenditure. Based on clinical trial data, it shows promising results for both weight management and type 2 diabetes control.
The head-to-head superiority over semaglutide in the DREAMS-3 trial is particularly noteworthy, suggesting the dual GLP-1/glucagon mechanism provides meaningful clinical benefits beyond single-agonist therapies.
For now, mazdutide is only approved in China under the brand name Xinermei. US and European patients will need to wait for ongoing clinical trials to complete and regulatory submissions to be filed, with potential FDA approval expected in 2026-2027.
As always, discuss any new treatment options with your healthcare provider to determine what’s right for your individual situation.
Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting any weight-loss or diabetes medication. Mazdutide is not FDA-approved in the United States as of this publication.